|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.630 USD | -8.77% |
|
-16.54% | +19.69% |
| 06-09 | Cartesian Therapeutics Signs Licensing Agreement With WestGene to Develop Therapies for Autoimmune Diseases | MT |
| 05-26 | Cartesian Therapeutics, Inc. Announces Executive Changes | CI |
| Market Cap | 254M 222M 206M 190M 358M 24.27B 365M 2.46B 963M 11.92B 952M 931M 41.16B | P/E 2026 * |
-2.08x | P/E 2027 * | -2.26x |
|---|---|---|---|---|---|
| Enterprise Value | 110M 96.54M 89.41M 82.27M 156M 10.53B 159M 1.07B 418M 5.17B 413M 404M 17.87B | EV / Sales 2026 * |
199x | EV / Sales 2027 * | -121x |
| Free-Float |
46.32% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cartesian Therapeutics, Inc.
| 1 day | -8.77% | ||
| 1 week | -16.54% | ||
| Current month | -17.18% | ||
| 1 month | -9.25% | ||
| 3 months | +45.53% | ||
| 6 months | +12.66% | ||
| Current year | +19.69% |
| 1 week | 8.25 |  | 10.56 |
| 1 month | 8.25 | | 11 |
| Current year | 5.6 | | 11 |
| 1 year | 5.6 | | 14.56 |
| 3 years | 5.6 | | 42.6 |
| 5 years | 5.6 | | 42.6 |
| 10 years | 5.6 | | 42.6 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 04-02 | Fiscal year | 22,740 | - | |||
| 04-02 | Fiscal year | 758,001 | 2.8594% | |||
| 04-02 | Fiscal year | 758,001 | 2.8594% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.77% | -16.54% | -35.21% | - | 254M | |
| -2.48% | -2.22% | +55.85% | +79.12% | 53.54B | |
| +0.32% | -6.13% | +56.42% | +128.26% | 54.18B | |
| -5.60% | -2.15% | +11.16% | +420.46% | 23.66B | |
| -1.55% | -4.11% | -20.21% | -17.75% | 22.78B | |
| +2.36% | +3.86% | +42.80% | -6.60% | 19.54B | |
| -0.42% | +0.08% | +38.34% | -27.70% | 17.82B | |
| -2.72% | -4.04% | +187.08% | +362.09% | 16.01B | |
| -1.15% | -3.07% | +45.33% | +654.85% | 15.37B | |
| -0.81% | +0.92% | +24.92% | +189.61% | 14.09B | |
| Average | -2.08% | -3.17% | +40.65% | +198.04% | 23.72B | |
| Weighted average by Cap. | -1.34% | -2.01% | +48.08% | +163.04% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 552K 484K 449K 413K 781K 52.86M 796K 5.35M 2.1M 25.96M 2.07M 2.03M 89.64M | 402K 352K 326K 300K 568K 38.43M 579K 3.89M 1.52M 18.87M 1.51M 1.47M 65.17M |
| Net income | -122M -107M -99.39M -91.45M -173M -11.71B -176M -1.18B -465M -5.75B -459M -449M -19.86B | -131M -115M -106M -97.71M -185M -12.51B -188M -1.27B -496M -6.14B -491M -480M -21.22B |
| Net Debt | -144M -126M -117M -107M -203M -13.73B -207M -1.39B -545M -6.74B -539M -527M -23.29B | -302M -265M -245M -226M -427M -28.91B -435M -2.92B -1.15B -14.2B -1.13B -1.11B -49.04B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/07/26 | $8.630 | -8.77% | 259,974 |
| 10/07/26 | $9.460 | -2.17% | 133,011 |
| 09/07/26 | $9.670 | -5.66% | 117,513 |
| 08/07/26 | $10.25 | +1.99% | 169,945 |
| 07/07/26 | $10.05 | -2.80% | 138,647 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RNAC Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
